161 results about "Metabolism disorder" patented technology

The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and / or atherosclerosis.

This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

This invention also provides a method to prevent, control, and treata lipid metabolism disorder, a biliary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodieasterases.

The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and / or atherosclerosis.

The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-β superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.

The invention relates to a synergistic bifunctional protein for regulating blood sugar and lipid. The synergistic bifunctional protein comprises a human GLP-1 analog and human FGF21. In one aspect, the invention provides a method for preparing the synergistic bifunctional protein, and on the other hand, the invention also provides an application of the synergistic bifunctional protein for treatment of type 2 diabetes, obesity, dyslipidemia, fatty liver disease and / or metabolism syndrome drugs. The synergistic bifunctional protein provided by the invention can synergistically regulate blood sugar and lipid levels in vivo, and meet the multiple needs of hypoglycemia, alleviation of liver fatty degeneration, weight reduction and improvement of circulating lipid metabolism disorder in type 2 diabetic patients.

Patients suffering from diabetic and / or dysmetabolic nephropathy are treated with L-carnitine or its alkanoyl derivatives.

The invention discloses a preparation of secoisolariciresinol diglucoside, including steps of: ethanol extracting flaxseed meal in a soxhlet extraction device, wherein concentrated solution is obtained by decompress concentrating the extract; edulcorating the extract by acid precipitation and centrifugation; obtaining crude product of secoisolariciresinol diglucoside by alkaline hydrolysis, regulating PH value of extract, decompress concentrating and drying subsequently; product of secoisolariciresinol diglucoside with high content of SDG is obtained by ethanol extracting the crude product. The inventive production process is simple, easy to industrialize, totally avoid using toxic organic solution, and avoid using separation medium such as silica gel, macroporous resin, gelatin. The invention is capable of keeping effective elements of polyphenol in raw material, so as to ensure good medicine efficacy of subsequent product, while in favor of security of subsequent usage. The product can be used to improve osteoporosis, metabolism disorder of blood lipid, obesity, depression caused by women's climacteric syndrome, and to prevent and treat diseases related to heart, prostate, colon and kidney.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

The invention discloses an additive for improving the dry matter intake of dairy cow feed in early lactation and relates to the additive for improving the dry matter intake of the dairy cow feed. The additive can solve the problems that the existing various phagostimulants, feed physiological regulating agents for promoting appetite and other artificial chemical synthetic preparations have highercost, residues in milk are easy to affect digestion and metabolism of ingredients and the like. The product comprises the following components in parts by weight: 8-10 parts of membranous milkvetch root, 8-10 parts of pilose Asiabell root, 8-9 parts of liquoric root, 6-7 parts of uniflower swisscentaury root, 5-6 parts of Chinese angelica, 5-6 parts of motherwort herb, 5-6 parts of acorn powder, 5-6 parts of tangerine peel, 5-6 parts of peppermint, 5-6 parts of Mongolian dandelion herb, 5-6 parts of parslane herb and 5-6 parts of Chinese magnoliavine fruit, is obtained by drying, crushing andscreening, and can be used for direct feeding after stirring uniformly, essentially condition the physiological functions of dairy cows in the early lactation, improve the dry matter intake of the feed and the milk yield, have no residue in the milk, improve the reproductive performance, further effectively reduce the occurrence of nutrition and metabolism disorder diseases and prolong the service years of the dairy cows.

The present invention demonstrates the therapeutic use of ketone esters for seizure disorders, Alzheimer's disease malignant brain cancer, and other cancers, which are associated with metabolic dysregulation. The administration of a ketogenic diet, such as ketone esters, while concurrently subjecting the patient to a hyperbaric, oxygen-enriched environment resulted in therapeutic ketosis. Optionally, the hyperbaric, oxygen-enriched environment is 100% oxygen at 2.5 ATA absolute. The ketone esters may be derived from acetoacetate and can include R,S-1,3-butanediol acetoacetate monoester, R,S-1,3-butanediol acetoacetate diester, or a combination of the two. The treatment may further include administering at least 10% ketone supplementation, such as acetoacetate, adenosine monophosphate kinase, 1,3-butanediol, or ketone ester, to the patient.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypersomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and / or a body weight disorder, and compositions associated therewith, are provided.

Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R is hydrogen, halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; R is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; one of R4 and R5 is hydrogen or hydroxy and the other is hydrogen; or R4 and R5 together are ═O; R6 is hydrogen or alkyl having one, two, three, four or five carbon atoms; or a pharmaceutically acceptable salt of the compound. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).

The present invention provides a method of preventing or treating human obesity, said method comprising ingesting a composition containing, calculated on dry matter: 10-100 wt. % protein hydrolysate; 0-90 wt. % intact protein; 0-50 wt. % carbohydrate; and wherein hydrolysed protein and intact protein together are present in a concentration (w / w) that exceeds the carbohydrate concentration (w / w). The invention also encompasses the use of the same composition in a method of preventing or treating lipid metabolism disorders and in a method for improving body appearance. Other aspects of the invention relate to nutritional beverages, snacks and soups that can advantageously be employed in accordance with the aforementioned methods.

The invention discloses a mutant fibroblast growth factor (FGF-21) and use of the mutant fibroblast growth factor in treating endocrine diseases. The amino acid sequence of the fibroblast growth factor-21 disclosed by the invention is shown as SEQ ID NO: 2, and the sequence of a gene for encoding the mutant fibroblast growth factor is shown as SEQ ID NO: 1. According to the invention, a wild typeFGF-21 is used as a template, two arginine (Arg) residues are introduced through a downstream primer, and a mutant is obtained through polymerase chain reaction (PCR). The strong basicity and positive charges in the physiological condition of Arg are mainly utilized so that the isoelectric point of FGF-21 is up-regulated, and FGF-21 binding to the surfaces of cell membranes is facilitated. The results of an animal experiment show that the mutant FGF-21 disclosed by the invention can more effectively reduce the blood glucose level in an animal, and furthermore, the mutant disclosed by the invention has the advantages of fast onset of drug action, lasting drug effect and the like in reducing the blood glucose level. The mutant GF-21 disclosed by the invention can be used as a medicine to treat endocrine diseases such as diabetes, metabolic syndrome, lipid metabolism disorder and the like.

The invention encompasses novel sulfide and disulfide compounds, compositions comprising sulfide and disulfide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The invention relates to 4-hydroxyisoleucine, isomers, analogs, lactones, salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. More particularly, the invention relates to the use of those compounds in the prevention and treatment of disorders of fat metabolism and related syndromes. The invention further relates to the use of those compounds in the prevention and treatment of obesity and related syndromes including, but not limited to, the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight, and more particularly loss of body fat.

The invention relates to the novel discovery that inhibiting a C / CLP modulates (e.g., inhibits) inflammation, as well as, bone and tissue destruction in arthritis. The present invention relates to compositions and methods for the treatment of bone metabolism and connective tissue disorders and diseases (e.g., bone metabolism disorders, osteoarthritis, psoriatic arthritis, rheumatoid arthritis, and osteoporosis) by modulating (e.g., inhibiting) at least one C / CLP. In particular where the inhibition of at least one C / CLP results in the inhibition of osteoclast activity, including but not limited to, osteoclast maturation, osteoclast differentiation, osteoclast proliferation, and osteoclastogenesis. One particular embodiment of the invention relates to inhibiting the expression or activity of one or more C / CLPs.

The invention discloses application of adipose-derived mesenchymal stem cell exosomes in preparation of a medicine for treating metabolic syndrome. The adipose-derived mesenchymal stem cell exosomes are prepared through the following method: (1) dispersing a stripped adipose tissue into a digestion solution to produce cell suspension; (2) centrifugating the cell suspension to form cell sediments, and separating and washing the sediments, thus obtaining an adipose-derived mesenchymal stem cell-containing blood vessel matrix component; (3) performing multiplication culture on ADSC (adipose-derived stem cell) in an in-vitro culture system, collecting supernate obtained by the multiplication culture for concentration, and adding an exosome extraction reagent into the concentrated supernate, thus obtaining the adipose-derived mesenchymal stem cell exosomes through extracting. The adipose-derived mesenchymal stem cell exosomes can effectively relieve insulin resistance and metabolic disorders and inhibit occurrence and development of the metabolic syndrome and non-alcoholic fatty liver disease to a certain extent.

The medicinal composition of effective parts of paeonol, its preparation method and application, is characterized in that the medicinal composition contains 10-40% of paeonol and 10-50% of paeonol total glycosides in terms of weight percentage; wherein, paeonol The total amount of phenol and total paeonol glycosides is not less than 50%. The preparation method is to soak paeonol medicinal material powder or decoction pieces in water, heat and distill, and place the distillate under cooling to precipitate and crystallize paeonol; Solution extraction, the extract and the filtrate are put on a macroporous adsorption resin column, firstly eluted with water, then with alcohol, and the alcohol eluate is collected; the alcohol is recovered under reduced pressure, concentrated and dried to obtain paeonol total glycosides; paeonol and The total glycosides of paeonol are mixed to prepare the composition of effective parts of paeonol. The effective part composition of paeonol cortex of the invention can be used to prepare medicines for preventing and treating fat metabolism diseases and cardiovascular and cerebrovascular diseases.

The invention belongs to the technical field of pharmacy. The invention discloses a flavonoid compound for preventing and treating the diabetes and medicament application thereof, wherein the flavonoid compound is homoplantagin and hispidulin and is separated from the whole Salvia plebeia R. Br. The homoplantagin and the hispidulin can be used for obviously reducing the blood sugar of the mouse which suffer from the alloxan diabetes, reducing the serum total cholesterol content and the triglyceride content, obviously reducing the generation of the nitrogen oxide in the endothelial cell caused by free fatty acid, improving the insulin resistance caused by the free fatty acid, and protecting the endothelial cell of the blood vessel. Therefore, the homoplantagin and the hispidulin have good functions for reducing the blood sugar and the blood fat, and protecting the endothelial cell of the blood vessel, and can be used for preparing the medicament for preventing and curing the diabetes and the cardiovascular disease such as the lipid metabolism dysfunction, the atherosclerosis, the coronary disease and the like caused by the diabetes.

The invention discloses a mutated human-source fibroblast growth factor and application in treating endocrine diseases. The amino acid sequence of the mutated human-source fibroblast growth factor-21 is shown as SEQ ID NO: 2, and the coding genetic sequence is shown as SEQ ID NO: 1. In the invention, a human blood cell nucleic acid is used as a template, FGF-21 genes in a normal human body can be cloned by means of a natural gene bank in quantity, a natural human FGF-21 sample bank can be established, and the natural mutant of the FGF-21 can be obtained by a high-flux screening method. Zoological experiment results prove that the mutated FGF-21 can more effectively reduce the blood sugar level in an animal body, and the mutant has the advantages of quick response, long efficacy duration and the like in the aspect of reducing the blood sugar level. The mutated FGF-21 can be used as medicament for treating diabetes mellitus, metabolic syndrome or lipid metabolism disorder and other endocrine diseases.

The present invention relates to a method for preventing and / or treating a fat metabolism disorder and its related conditions, comprising administering an effective amount of plasminogen to a subject susceptible to or suffering from a fat metabolism disorder and its related conditions, to reduce an abnormal fat deposition at various sites of the body, thereby achieving the purpose of preventing and / or treating a fat metabolism disorder and its related conditions or complications.

A method of treating or preventing a subject's health problem that is related to an underlying disorder in the functioning of the metabolic system of the subject includes the step of administering a therapeutically effective dosage of glycine. For health problems associated with the subject's bones, cartilage or connective tissue, including degenerative diseases such as arthrosis and arthritis, injuries due to physical trauma, the condition of one's skin, teeth, gums, finger nails, eyes, ears, vocal chords or muscles, or diseases such as osteoporosis, asthma, multiple sclerosis or atherosclerosis, the administering step involves daily ingesting glycine at a rate in the range of 0.1 to 0.7 g / Kg of the subject's body weight.

The invention belongs to the field of traditional Chinese medicines and relates to an uncaria extract and new application thereof in preparing medicines for reducing blood fat and resisting cardiac hypertrophy. Proved by the animal experiment, the uncaria ethanol extract has the functions of reducing blood fat and resisting cardiac hypertrophy, and especially can reduce the triglyceride level in blood, the weight ratio of the left ventricle to the whole heart, and the weight ratio of the left ventricle to the right ventricle. The uncaria ethanol extract can be used as the raw material for pharmaceutical preparations to further prepare the medicines for reducing blood fat and resisting cardiac hypertrophy, so that the medicines can be used for treating disturbance of lipid metabolism and metabolic syndromes, and preventing and curing atherosclerosis, and hypertensive cardiopathy caused by hypertension and cardiac hypertrophy, including myocardial ischemia, myocardial damage, myocardial infarction and heart failure.

The invention is directed to thiocarbonate compounds of Formula (I)-(III) and methods of treating atherosclerosis, neuropathy, nephropathy, retinopathy, inflammatory disorders, COPD, cardiovascular diseases, metabolic disorders, type I diabetes mellitus, type II diabetes mellitus, LADA, Wolfram Syndrome 1, Wolcott-Rallison syndrome, metabolic syndrome, dyslipidemia, hyperglycemia, or insulin resistance. The compounds of the invention are also useful for protecting pancreatic beta-cells and for reducing free fatty acids, triglycerides, advanced glycated end products, ROS, lipid peroxidation, tissue and plasma TNFalpha and IL6 levels, or for delaying or preventing cardiovascular complications associated with atherosclerosis.

The invention discloses an adsorbent based on photosynthetic spore bacterium treatment of soil heavy metals, and a preparation method thereof. The preparation method of the adsorbent comprises the following steps: preparing a composite powder, preparing a bacterium culture solution, preparing a photosynthetic bacterium culture solution, preparing a spore bacterium culture solution, and culturing photosynthetic bacteria. The photosynthetic bacteria and the spore bacteria promote the growth of hyperaccumulators, enrich microbial florae, promote the root expansion depth, improve the selectivity to heavy metals, inhibit the transshipment trend of the heavy metals from the root to the aboveground part, shorten the repairing time and accelerate the repairing efficiency. The heavy metal ion enrichment ability of the photosynthetic bacteria and the spore bacteria and the heavy metal ion adsorption and removal ability of zeolite, vermiculite and agriculture and forestry waste active carbon arecombined to make the heavy metal ions adsorbed into the adsorbent, solidify the soil heavy metal ions and transform the heavy metal ions into a low-toxicity form, so the soil heavy metal ions are effectively adsorbed, and the influence of plant cell metabolism disorder caused by the heavy metals on normal growth of the plants is reduced.

Compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities are disclosed. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including but not limited to, diabetes, mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X. The present invention also relates to methods of treating Type I diabetes, beneficially regulating gastrointestinal motility, treating impaired glucose tolerance, treating postprandial hyperglycemia, treating obesity and treating Syndromne X, comprising administration of a therapeutically effective amount of certain compounds, as described herein.